Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. Zeidner JF, Lin TL, Welkie RL, Curran E, et al. J Clin Oncol 2025;43:2606-2615.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zeidner JF, Lin TL, Welkie RL, Curran E, et al. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol 2025;43:2606-2615.
PMID: 40504618